Next-Generation Implantable Drug Delivery System with AI-Powered Real-Time Monitoring

A revolutionary drug delivery system that integrates implantable devices with AI-driven decision-making, real-time monitoring, and personalized treatment to combat opioid overdoses and other medical emergencies.

The original patent disclosed a single-use drug delivery device for treating opioid overdoses. However, this invention has limitations, including the lack of real-time monitoring, limited adaptability to individual patients, and reliance on manual intervention. The next-generation system addresses these limitations by incorporating AI-powered decision-making, neural interfaces, and real-time monitoring to provide more effective and personalized treatment.

The inventive concept comprises an implantable drug delivery device with a neural interface for real-time monitoring of the recipient's physiological parameters, an AI-powered decision-making module for automatically detecting overdose events and triggering drug release, and a wearable device for detecting opioid overdose events. The system can deliver personalized cocktails of drugs tailored to the recipient's genetic profile and medical history. The biohybrid implantable device features a living cell-based sensor for detecting overdose events and a microfluidic drug delivery system for releasing therapeutic agents. The decentralized drug delivery network enables real-time monitoring and coordinated response to overdose events across a plurality of implantable devices.

The new claims introduce significant advancements over the original patent, including the integration of AI-powered decision-making, real-time monitoring, and personalized treatment. The use of neural interfaces, biohybrid sensors, and decentralized networks represents a paradigm shift in drug delivery technology, providing a more effective and adaptable solution for combating opioid overdoses and other medical emergencies.

Alternative embodiments may include variations in the neural interface design, AI algorithms, and sensor arrays. Additionally, the system could be adapted for use in different medical applications, such as diabetes management or cardiovascular disease treatment. The decentralized network could be expanded to include other devices, such as wearable fitness trackers or mobile health applications.

The next-generation drug delivery system has significant commercial potential in the medical device and pharmaceutical industries. The system's ability to provide personalized treatment and real-time monitoring addresses a critical need in the opioid epidemic, with potential applications in emergency response, hospital care, and outpatient treatment. The decentralized network and AI-powered decision-making capabilities also open up opportunities for remote patient monitoring and telemedicine.